VIENNA — In this exclusive video from the International Liver Congress 2019, Gideon M. Hirschfield, MD, from the Toronto Center for Liver Disease and the University of Toronto in Canada, discusses the long-term effects of Ocaliva in patients with primary biliary cholangitis on immune and inflammatory markers.
In the study Hirschfield presented this year, Ocaliva (obeticholic acid, Intercept) demonstrated not only improvements in markers of cholestasis but also improved markers of inflammation including C-reaction protein.
“Studies like this are very important as we develop new drugs

Source link